Management of Diabetes and Hyperglycemia in Hospitals
Tóm tắt
Từ khóa
Tài liệu tham khảo
Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE: Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 87:978–982, 2002
Van den Berghe G, Wouters P, Weekers F, VerWaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in critically ill patients. N Engl J Med 345:1359–1367, 2001
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 26 (Suppl. 1):S5–S20, 2003
Tierney E: Data from the National Hospital Discharge Survey Database 2000, Center of Disease Control and Prevention, Division of Diabetes Translation, Atlanta, GA, 2003. Personal communication
Levetan CS, Passaro M, Jablonski K, Kass M, Ratner RE: Unrecognized diabetes among hospitalized patients. Diabetes Care 21:246–249, 1998
Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, Malmberg K: Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 359:2140–2144, 2002
Greci LS, Kailasam M, Malkani S, Katz DL, Hulinsky I, Ahmadi R, Nawaz H: Utility of HbA1c levels for diabetes case finding in hospitalized patients with hyperglycemia. Diabetes Care 26:1064–1068, 2003
Aubert R, Geiss L, Ballard D, Cocanougher B, Herman W: Diabetes-Related Hospitalization and Hospital Utilization. 2nd ed. Bethesda, MD, National Institutes of Health, 1995, p. 555–556
Joshi N, Caputo G, Weitekamp M, Karchmer A: Infections in patients with diabetes mellitus. N Engl J Med 341:1906–1912, 1999
Mowat A, Baum J: Chemotaxis of polymorphonuclear leukocytes from patients with diabetes mellitus. N Engl J Med 284:621–627, 1971
Bagdade J, Root R, Bulger R: Impaired leukocyte function in patients with poorly controlled diabetes. Diabetes 23:9–15, 1974
Bagdade JD, Stewart M, Walters E: Impaired granulocyte adherence. A reversible defect in host defense in patients with poorly controlled diabetes. Diabetes 27:677–681, 1978
van Oss CJ, Border JR: Influence of intermittent hyperglycemic glucose levels on the phagocytosis of microorganisms by human granulocytes in vitro. Immunol Commun 7:669–676, 1978
Davidson N, Sowden J, Fletcher J: Defective phagocytosis in insulin-controlled diabetics: evidence for a reaction between glucose and opsonizing proteins. J Clin Pathol 37:783–786, 1984
Alexiewicz J, Kumar D, Smogorzewski M, Klin M, Massry S: Polymorphonuclear leukocytes in non-insulin-dependent diabetes mellitus: abnormalities in metabolism and function. Ann Intern Med 123:919–924, 1995
Leibovici L, Yehezkelli Y, Porter A, Regev A, Krauze I, Harrell D: Influence of diabetes mellitus and glycemic control on the characteristics and outcome of common infections. Diabet Med 13:457–463, 1996
Kwoun M, Ling P, Lydon E, Imrich A, Qu Z, Palombo J, Bistrian. B: Immunologic effects of acute hyperglycemia in nondiabetic rats. J Parenter Enteral Nutr 21:91–95, 1997
McManus L, Bloodworth R, Prihoda T, Blodgett J, Pinckard R: Agonist-dependent failure of neutrophil function in diabetes correlates with extent of hyperglycemia. J Leukocyte Biol 70:395–404, 2001
MacRury S, Gemmell C, Paterson K, MacCush A: Changes in phagocytic function with glycaemic control in diabetic patients. J Clin Pathol 42:1143–1147, 1989
Rassias A, Marrin C, Arruda J, Whalen P, Beach M, Yeager M: Insulin infusion improved neutrophil function in diabetic cardiac surgery patients. Anesth Analg 88:1011–1016, 1999
Rassias A, Givan A, Marrin C, Whalen K, Pahl J, Yeager M: Insulin increases neutrophil count and phagocytic capacity after cardiac surgery. Anesth Analg 94:1113–1119, 2002
Repine J, Clawson C, Goetz F: Bactericidal function of neutrophils from patients with acute bacterial infections and from diabetes. J Infect Dis 142:869–875, 1980
Nielson C, Hindson D: Inhibition of polymorphonuclear leukocyte respiratory burst by elevated glucose concentrations in vitro. Diabetes 38:1031–1035, 1989
Wilson RM, Reeves WG: Neutrophil phagocytosis and killing in insulin-dependent diabetes. Clin Exp Immunol 63:478–484, 1986
Sheetz M, King G: Molecular understanding of hyperglycemia’s adverse effects for diabetic complications. JAMA 288:2579–2588, 2002
Oldenborg P, Sehlin J: Hyperglycemia in vitro attenuates insulin-stimulated chemokinesis in normal human neutrophils: role of protein kinase C activation. J Leukocyte Biol 65:635–640, 1999
Liu BF, Miyata S, Kojima H, Uriuhara A, Kusunoki H, Suzuki K, Kasuga M: Low phagocytic activity of resident peritoneal macrophages in diabetic mice: relevance to the formation of advanced glycation end products. Diabetes 48:2074–2082, 1999
Ortmeyer J, Mohsenin V: Inhibition of phospholipase D and superoxide generation by glucose in diabetic neutrophils. Life Sciences 59:255–262, 1996
Perner A, Nielsen S, Rask-Madsen J: High glucose impairs superoxide production from isolated blood neutrophils. Intensive Care Med 29:642–645, 2003
Sato N, Kashima K, Ohtani K, Shimizu H, Mori M: Epalrestat, an aldose reductase inhibitor, improves an impaired generation of oxygen-derived free radicals by neutrophils from poorly controlled NIDDM patients. Diabetes Care 20:995–998, 1997
Boland O, Blackwell C, Clarke B, Ewing D: Effects of ponalrestat, an aldose reductase inhibitor, on neutrophil killing of Escherichia coli and autonomic function in patients with diabetes mellitus. Diabetes 42:336–340, 1993
Mazade MA, Edwards MS: Impairment of type III group B Streptococcus-stimulated superoxide production and opsonophagocytosis by neutrophils in diabetes. Mol Genet Metab 73:259–267, 2001
Black CT, Hennessey PJ, Andrassy RJ: Short-term hyperglycemia depresses immunity through nonenzymatic glycosylation of circulating immunoglobulin. J Trauma 30:830–832; discussion 832–833, 1990
von Kanel R, Mills P, Dimsdale J: Short-term hyperglycemia induces lymphopenia and lymphocyte subset redistribution. Life Sciences 69:255–262, 2001
Bouter KP, Meyling FH, Hoekstra JB, Masurel N, Erkelens DW, Diepersloot RJ: Influence of blood glucose levels on peripheral lymphocytes in patients with diabetes mellitus. Diabetes Res 19:77–80, 1992
Kersten J, Schmeling T, Orth K, Pagel P, Warltier D: Acute hyperglycemia abolishes ischemic preconditioning in vivo. Am J Physiol 275:H721–H725, 1998
Kersten J, Toller W, Tessmer J, Pagel P, Warltier D: Hyperglycemia reduces coronary collarteral blood flow through a nitric oxide-mediated mechanism. Am J Physiol 281:H2097–H2104, 2001
Ceriello A, Quagliaro L, D’Amico M, Di Filippo C, Marfella R, Nappo F, Berrino L, Rossi F, Giugliano D: Acute hyperglycemia induces nitrotyrosine formation and apoptosis in perfused heart from rat. Diabetes 51:1076–1082, 2002
Verma S, Maitland A, Weisel R, Li S, Fedak P, Pomroy N, Mickle D, Li R, Ko L, Rao V: Hyperglycemia exaggerates ischemia-reperfusion-induced cardiomyocyte injury: reversal with endothelin antagonism. J Thorac Cardiovasc Surg 123:1120–1124, 2002
D’Amico M, Marfella R, Nappo F, Di Filippo C, De Angelis L, Berrino L, Rossi F, Giugliano D: High glucose induces ventricular instability and increases vasomotor tone in rats. Diabetologia 44:464–470, 2001
Marfella R, Nappo F, Angelis LD, Paolisso G, Tagliamonte M, Giugliano D: Hemodynamic effects of acute hyperglycemia in type 2 diabetic patients. Diabetes Care 23:658–663, 2000
Marfella R, Nappo F, Angelis LD, Siniscalshi M, Rossi F, Giugliano D: The effect of acute hyperglycaemia on QTc duration in healthy man. Diabetologia 43:571–575, 2000
Cinar Y, Senyol A, Duman K: Blood viscosity and blood pressure: role of temperature and hyperglycemia. American J Hypertens 14:433–438, 2001
McKenna K, Smith D, Tormey W, Thompson C: Acute hyperglycaemia causes elevation in plasma atrial natriuretic peptide concentrations in type 1 diabetes mellitus. Diabet Med 17:512–517, 2000
Davi G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, Patrono C: Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 322:1769–1774, 1990
Knobler H, Savion N, Shenkman B, Kotev-Emeth S, Varon D: Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients. Thromb Res 90:181–190, 1998
Davi G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, Pennese E, Vitacolonna E, Bucciarelli T, Costantini F, Capani F, Patrono C: In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99:224–229, 1999
Sakamoto T, Ogawa H, Kawano H, Hirai N, Miyamoto S, Takazoe K, Soejima J, Kugiyama K: Rapid change of platelet aggregability in acute hyperglycemia. Detection by a novel laser-light scattering method. Thrombosis & Hemostasis 83:475–479, 2000
Gresele P, Guglielmini G, DeAngelis M, Ciferri S, Ciofetta M, Falcinelli E, Lalli C, Ciabattoni G, Davi G, Bolli G: Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol 41:1013–1020, 2003
Pandolfi A, Giaccari A, Cilli C, alberta M, Morviducci L, Filippis ED, Buongiorno A, Pellegrini G, Capani F, Consoli A: Acute hyperglycemia and acute hyperinsulinemia decrease plasma fibrinolytic activity and increase plaminogen activator inhibitor type 1 in the rat. Acta Diabetologica 38:71–77, 2001
Morohoshi M, Fujisawa K, Uchimura I, Numano F: Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro. Diabetes 45:954–959, 1996
Kado S, Nagase T, Nagata N: Circulating levels of interleukin-6, its soluble receptor and interleukin-6/interleukin-6 receptor complexes in patients with type 2 diabetes mellitus. Acta Diabetol 36:67–72, 1999
Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW: Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82:4196–4200, 1997
Pampfer S, Vanderheyden I, De Hertogh R: Increased synthesis of tumor necrosis factor-α in uterine explants from pregnant diabetic rats and in primary cultures of uterine cells in high glucose. Diabetes 46:1214–1224, 1997
Meldrum DR, Donnahoo KK: Role of TNF in mediating renal insufficiency following cardiac surgery: evidence of a postbypass cardiorenal syndrome. J Surg Res 85:185–199, 1999
Guha M, Bai W, Nadler JL, Natarajan R: Molecular mechanisms of tumor necrosis factor alpha gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways. J Biol Chem 275:17728–17739, 2000
Hattori Y, Hattori S, Sato N, Kasai K: High-glucose-induced nuclear factor kappaB activation in vascular smooth muscle cells. Cardiovasc Res 46:188–197, 2000
Coughlan MT, Oliva K, Georgiou HM, Permezel JM, Rice GE: Glucose-induced release of tumour necrosis factor-alpha from human placental and adipose tissues in gestational diabetes mellitus. Diabet Med 18:921–927, 2001
Lin Y, Rajala MW, Berger JP, Moller DE, Barzilai N, Scherer PE: Hyperglycemia-induced production of acute phase reactants in adipose tissue. J Biol Chem 276:42077–42083, 2001
Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D: Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106:2067–2072, 2002
Li D, Zhao L, Liu M, Du X, Ding W, Zhang J, Mehta JL: Kinetics of tumor necrosis factor alpha in plasma and the cardioprotective effect of a monoclonal antibody to tumor necrosis factor alpha in acute myocardial infarction. Am Heart J 137:1145–1152, 1999
Das UN: Free radicals, cytokines and nitric oxide in cardiac failure and myocardial infarction. Mol Cell Biochem 215:145–152, 2000
Meldrum DR, Dinarello CA, Shames BD, Cleveland JC, Jr., Cain BS, Banerjee A, Meng X, Harken AH: Ischemic preconditioning decreases postischemic myocardial tumor necrosis factor-alpha production: potential ultimate effector mechanism of preconditioning. Circulation 98:II214–II218; discussion II218–II219, 1998
Mallat Z, Corbaz A, Scoazec A, Besnard S, Leseche G, Chvatchko Y, Tedgui A: Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 104:1598–1603, 2001
Romeo G, Liu W, Asnaghi V, Kern T, Lorenzi M: Activation of nuclear factor-κB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes 51:2241–2248, 2002
Nishikawa T, Edelstein D, Brownlee M: The missing link: a single unifying mechanism for diabetic complications. Kidney Int Suppl 77:S26–S30, 2000
Yerneni KK, Bai W, Khan BV, Medford RM, Natarajan R: Hyperglycemia-induced activation of nuclear transcription factor κB in vascular smooth muscle cells. Diabetes 48:855–864, 1999
Morigi M, Angioletti S, Imberti B, Donadelli R, Micheletti G, Figliuzzi M, Remuzzi A, Zoja C, Remuzzi G: Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. J Clin Invest 101:1905–1915, 1998
Hofmann MA, Schiekofer S, Kanitz M, Klevesath MS, Joswig M, Lee V, Morcos M, Tritschler H, Ziegler R, Wahl P, Bierhaus A, Nawroth PP: Insufficient glycemic control increases nuclear factor-κB binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetes. Diabetes Care 21:1310–1316, 1998
Schiekofer NM, Andrassy M, Chen J, Rudofsky G, Schneider J, Wendt T, Stefan N, Humpert P, Fritsche A, Stumvoll M, Schleicher E, Haring H, Nawroth P, Bierhaus A: Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor-κB in PBMCs. Diabetes 52:621–633, 2003
Marfella R, Quagliaro L, Nappo F, Ceriello A, Giugliano D: Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest 108:635–636, 2001
Calles-Escandon J, Cipolla M: Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 22:36–52, 2001
Goligorsky MS, Chen J, Brodsky S: Workshop: endothelial cell dysfunction leading to diabetic nephropathy: focus on nitric oxide. Hypertension 37:744–748, 2001
Williams S, Goldfine A, Timimi F, Ting H, Roddy M, Simonson D, Roddy M, Simonson D, Creager M: Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 97:1695–1701, 1998
Kawano H, Motoyama T, Hirashima O, Hirai N, Miyao Y, Sakamoto T, Kugiyama K, Ogawa H, Yasue H: Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 34:146–154, 1999
Shige H, Ishikawa T, Suzukawa M, Ito T, Nakajima K, Higashi K, Ayaori M, Tabata S, Ohsuzu F, Nakamura H: Endothelium-dependent flow-mediated vasodilation in the postprandial state in type 2 diabetes mellitus. Am J Cardiol 84:1272–1274, A1279, 1999
Title LM, Cummings PM, Giddens K, Nassar BA: Oral glucose loading acutely attenuates endothelium-dependent vasodilation in healthy adults without diabetes: an effect prevented by vitamins C and E. J Am Coll Cardiol 36:2185–2191, 2000
Beckman J, Goldfine A, Gordon M, Creager M: Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. Circulation 103:1618–1623, 2001
Giugliano D, Marfella R, Coppola L, Verrazzo G, Acampora R, Giunta R, Nappo F, Lucarelli C, D’Onofrio F: Vascular effects of acute hyperglycemia in humans are reversed by L-arginine: evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 95:1783–1790, 1997
Bagg W, Whalley G, Sathu A, Gamble G, Sharpe N, Braatvedt G: The effect of acute hyperglycaemia on brachial artery flow mediated dilatation in normal volunteers. Austral NZ J Med 30:344–350, 2000
Brodsky SV, Morrishow AM, Dharia N, Gross SS, Goligorsky MS: Glucose scavenging of nitric oxide. Am J Physiol Renal Physiol 280:F480–F486, 2001
Myers RE, Yamaguchi S: Nervous system effects of cardiac arrest in monkeys: preservation of vision. Arch Neurol 34:65–74, 1977
Pulsinelli WA, Waldman S, Rawlinson D, Plum F: Moderate hyperglycemia augments ischemic brain damage: a neuropathologic study in the rat. Neurology 32:1239–1246, 1982
Prado R, Ginsberg MD, Dietrich WD, Watson BD, Busto R: Hyperglycemia increases infarct size in collaterally perfused but not end-arterial vascular territories. J Cereb Blood Flow Metab 8:186–192, 1988
Huang N, Wei J, Quast M: A comparison of the early development of ischemic brain dmage in normoglycemic and hyperglycemic rats using magnetic resonance imaging. Experimental Brain Research 109:33–42, 1996
Li PA, Kristian T, Shamloo M, Siesjo K: Effects of preischemic hyperglycemia on brain damage incurred by rats subjected to 2.5 or 5 minutes of forebrain ischemia. Stroke 27:1592–1601; discussion 1601–1592, 1996
Kawai N, Keep RF, Betz AL, Nagao S: Hyperglycemia induces progressive changes in the cerebral microvasculature and blood-brain barrier transport during focal cerebral ischemia. Acta Neurochir Suppl. (Wien) 71:219–221, 1998
Kawai N, Keep R, Betz A: Hyperglycemia and the vascular effects of cerebral ischemia. Acta Neurochirugica - Supplementum 70:27–29, 1997
Lin B, Ginsberg M, Busto R: Hyperglycemic exacerbation of neuronal damage following forebrain ischemia: microglial, astrocytic and endothelial alterations. Acta Neuropathologica 96:610–620, 1998
Gisselsson L, Smith M, Siesjo B: Hyperglycemia and focal brain ischemia. J Cereb Blood Flow Metab 19:288–297, 1999
Hoxworth JM, Xu K, Zhou Y, Lust WD, LaManna JC: Cerebral metabolic profile, selective neuron loss, and survival of acute and chronic hyperglycemic rats following cardiac arrest and resuscitation. Brain Res 821:467–479, 1999
Li P, Shuaib A, Miyashita H, He Q, Siesjo B, Warner D: Hyperglycemia enhances extracellular glutamate accumulation in rats subjected to forebrain ischemia. Stroke 31:183–192, 2000
Capes S, Hunt D, Malmberg K, Pathak P, Gerstein H: Stress hyperglycemia and prognosis of stroke in nodiabetic and diabetic patients: a systematic overview. Stroke 32:2426–2432, 2001
Park WS, Chang YS, Lee M: Effects of hyperglycemia or hypoglycemia on brain cell membrane function and energy metabolism during the immediate reoxygenation-reperfusion period after acute transient global hypoxia-ischemia in the newborn piglet. Brain Res 901:102–108, 2001
Rytter A, Cronberg T, Asztely F, Nemali S, Wieloch T: Mouse hippocampal organotypic tissue cultures exposed to in vitro “ischemia” show selective and delayed CA 1 damage that is aggravated by glucose. J Cereb Blood Flow Metab 23:23–33, 2003
Ginsberg MD, Prado R, Dietrich WD, Busto R, Watson BD: Hyperglycemia reduces the extent of cerebral infarction in rats. Stroke 18:570–574, 1987
Sieber FE: The neurologic implications of diabetic hyperglycemia during surgical procedures at increased risk for brain ischemia. J Clin Anesth 9:334–340, 1997
Venables GS, Miller SA, Gibson G, Hardy JA, Strong AJ: The effects of hyperglycaemia on changes during reperfusion following focal cerebral ischaemia in the cat. J Neurol Neurosurg Psychiatry 48:663–669, 1985
Anderson RE, Tan WK, Martin HS, Meyer FB: Effects of glucose and PaO2 modulation on cortical intracellular acidosis, NADH redox state, and infarction in the ischemic penumbra. Stroke 30:160–170, 1999
Kraig RP, Petito CK, Plum F, Pulsinelli WA: Hydrogen ions kill brain at concentrations reached in ischemia. J Cereb Blood Flow Metab 7:379–386, 1987
Petito CK, Kraig RP, Pulsinelli WA: Light and electron microscopic evaluation of hydrogen ion-induced brain necrosis. J Cereb Blood Flow Metab 7:625–632, 1987
Guyot LL, Diaz FG, O’Regan MH, Song D, Phillis JW: The effect of streptozotocin-induced diabetes on the release of excitotoxic and other amino acids from the ischemic rat cerebral cortex. Neurosurgery 48:385–390; discussion 390–381, 2001
Schurr A, Payne RS, Miller JJ, Tseng MT: Preischemic hyperglycemia-aggravated damage: evidence that lactate utilization is beneficial and glucose-induced corticosterone release is detrimental. J Neurosci Res 66:782–789, 2001
Christensen H, Boysen G: Blood glucose increases early after stroke onset: a study on serial measurements of blood glucose in acute stroke. Eur J Neurol 9:297–301, 2002
Ishii H, Arai T, Segawa H, Morikawa S, Inubushi T, Fukuda K: Effects of propofol on lactate accumulation and oedema formation in focal cerebral ischaemia in hyperglycaemic rats. Br J Anaesth 88:412–417, 2002
Parsons MW, Li T, Barber PA, Yang Q, Darby DG, Desmond PM, Gerraty RP, Tress BM, Davis SM: Combined (1)H MR spectroscopy and diffusion-weighted MRI improves the prediction of stroke outcome. Neurology 55:498–505, 2000
Parsons M, Barber P, Desmond P, Baird T, Darby D, Byrnes G, Tress B, Davis S: Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study. Ann Neurol 52:20–28, 2002
Dietrich WD, Alonso O, Busto R: Moderate hyperglycemia worsens acute blood-brain barrier injury after forebrain ischemia in rats. Stroke 24:111–116, 1993
Els T, Rother J, Beaulieu C, de Crespigny A, Moseley M: Hyperglycemia delays terminal depolarization and enhances repolarization after peri-infarct spreading depression as measured by serial diffusion MR mapping. J Cereb Blood Flow Metab 17:591–595, 1997
Li P, Rasquinha I, He Q, Siesjo B, Csiszar K, Boyd C, MacManus J: Hyperglycemia enhances DNA fragmentation after transient cerebral ischemia. J Cereb Blood Flow Metab 21:568–576, 2001
Lin B, Ginsberg MD, Busto R: Hyperglycemic but not normoglycemic global ischemia induces marked early intraneuronal expression of beta-amyloid precursor protein. Brain Res 888:107–116, 2001
Ste-Marie L, Hazell AS, Bemeur C, Butterworth R, Montgomery J: Immunohistochemical detection of inducible nitric oxide synthase, nitrotyrosine and manganese superoxide dismutase following hyperglycemic focal cerebral ischemia. Brain Res 918:10–19, 2001
Li P, Liu G, He Q, Floyd R, Siesjo B: Production of hydroxyl free radical by brain tissues in hyperglycemic rats subjected to transient forebrain ischemia. Free Rad Biol Med 27:1033–1040, 1999
Lockhart B, Bonhomme N, Roger A, Dorey G, Casara P, Lestage P: Protective effect of the antioxidant 6-ethoxy-2,2-pentamethylen-1,2-dihydroquinoline (S 33113) in models of cerebral neurodegeneration. Eur J Pharmacol 416:59–68, 2001
Prado R, Watson BD, Wester P: Effects of nitric oxide synthase inhibition on cerebral blood flow following bilateral carotid artery occlusion and recirculation in the rat. J Cereb Blood Flow Metab 13:720–723, 1993
Wang MJ, Huang HM, Hsieh SJ, Jeng KC, Kuo JS: Resveratrol inhibits interleukin-6 production in cortical mixed glial cells under hypoxia/hypoglycemia followed by reoxygenation. J Neuroimmunol 112:28–34, 2001
Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787–790, 2000
Booth G, Stalker TJ, Lefer AM, Scalia R: Elevated ambient glucose induces acute inflammatory events in the microvasculature: effects of insulin. Am J Physiol Endocrinol Metab 280:E848–E856, 2001
Giardino I, Edelstein D, Brownlee M: BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. J Clin Invest 97:1422–1428, 1996
Graier WF, Posch K, Fleischhacker E, Wascher TC, Kostner GM: Increased superoxide anion formation in endothelial cells during hyperglycemia: an adaptive response or initial step of vascular dysfunction? Diabetes Res Clin Pract 45:153–160, 1999
Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P: Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Metab 85:2970–2973, 2000
Du X, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M: Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 108:1341–1348, 2001
Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon KM: Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 105:1656–1662, 2002
Sampson M, Davies I, Brown J, Ivory K, Hughes D: Monocyte and neutrophil adhesion molecule expression during actue hyperglycemia and after antioxidant treatment in type 2 diabetes and control patients. Arterio Thromb Vasc Biol 22:1187–1193, 2002
Malmberg K, for the DIGAMI study group: Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 314:1512–1515, 1997
Dandona P, Aljada A, Mohanty P: The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm. Diabetologia 45:924–930, 2002
Dandona P, Aljada A, Bandyopadhyay A: The potential therapeutic role of insulin in acute myocardial infarction in patients admitted to intensive care and in those with unspecified hyperglycemia. Diabetes Care 26:516–519, 2003
Melidonis A, Stefanidis A, Tournis S, Manoussakis S, Handanis S, Zairis M, Dadiotis L, Foussas S: The role of strict metabolic control by insulin infusion on fibrinolytic profile during an acute coronary event in diabetic patients. Clin Cardiol 23:160–164, 2000
Machtey I, Syrkis I, Nissimov MR, Lobel H: Potassium, glucose and insulin administration in acute myocardial infarction: a five-year study. J Am Geriatr Soc 24:534–537, 1976
Rogers WJ, Stanley AW, Jr., Breinig JB, Prather JW, McDaniel HG, Moraski RE, Mantle JA, Russell RO, Jr., Rackley CE: Reduction of hospital mortality rate of acute myocardial infarction with glucose-insulin-potassium infusion. Am Heart J 92:441–454, 1976
Russell RO, Jr., Rogers WJ, Mantle JA, McDaniel HG, Rackley CE: Glucose-insulin-potassium, free fatty acids and acute myocardial infarction in man. Circulation 53:I207–209, 1976
Rogers WJ, Russell RO, Jr., McDaniel HG, Rackley CE: Acute effects of glucose-insulin-potassium infusion on myocardial substrates, coronary blood flow and oxygen consumption in man. Am J Cardiol 40:421–428, 1977
Rackley CE, Russell RO, Jr., Rogers WJ, Mantle JA, McDaniel HG: Glucose-insulin-potassium infusion in acute myocardial infarction: review of clinical experience. Postgrad Med 65:93–99, 1979
Mantle JA, Rogers WJ, Smith LR, McDaniel HG, Papapietro SE, Russell RO, Jr., Rackley CE: Clinical effects of glucose-insulin-potassium on left ventricular function in acute myocardial infarction: results from a randomized clinical trial. Am Heart J 102:313–324, 1981
McDaniel HG, Papapietro SE, Rogers WJ, Mantle JA, Smith LR, Russell RO, Jr., Rackley CE: Glucose-insulin-potassium induced alterations in individual plasma free fatty acids in patients with acute myocardial infarction. Am Heart J 102:10–15, 1981
McDaniel HG, Rogers WJ, Russell RO, Jr., Rackley CE: Improved myocardial contractility with glucose-insulin-potassium infusion during pacing in coronary artery disease. Am J Cardiol 55:932–936, 1985
Lazar HL: Enhanced preservation of acutely ischemic myocardium and improved clinical outcomes using glucose-insulin-potassium (GIK) solutions. Am J Cardiol 80:90A–93A, 1997
Lazar HL, Chipkin S, Philippides G, Bao Y, Apstein C: Glucose-insulin-potassium solutions improve outcomes in diabetics who have coronary artery operations. Ann Thorac Surg 70:145–150, 2000
Lazar HL, Philippides G, Fitzgerald C, Lancaster D, Shemin RJ, Apstein C: Glucose-insulin-potassium solutions enhance recovery after urgent coronary artery bypass grafting. J Thorac Cardiovasc Surg 113:354–360; discussion 360–352, 1997
Lazar HL, Zhang X, Rivers S, Bernard S, Shemin RJ: Limiting ischemic myocardial damage using glucose-insulin-potassium solutions. Ann Thorac Surg 60:411–416, 1995
Lazar HL, Fitzgerald C, Gross S, Heeren T, Aldea GS, Shemin RJ: Determinants of length of stay after coronary artery bypass graft surgery. Circulation 92:II20–II24, 1995
Apstein CS: Glucose-insulin-potassium for acute myocardial infarction: remarkable results from a new prospective, randomized trial. Circulation 98:2223–2226, 1998
Scott JF, Robinson GM, French JM, O’Connell JE, Alberti KG, Gray CS: Glucose potassium insulin infusions in the treatment of acute stroke patients with mild to moderate hyperglycemia: the Glucose Insulin in Stroke Trial (GIST). Stroke 30:793–799, 1999
Cave AC, Ingwall JS, Friedrich J, Liao R, Saupe KW, Apstein CS, Eberli FR: ATP synthesis during low-flow ischemia: influence of increased glycolytic substrate. Circulation 101:2090–2096, 2000
Marano L, Bestetti A, Lomuscio A, Tagliabue L, Castini D, Tarricone D, Dario P, Tarolo GL, Fiorentini C: Effects of infusion of glucose-insulin-potassium on myocardial function after a recent myocardial infarction. Acta Cardiol 55:9–15, 2000
Scott J, Robinson G, French J, O’Connell J, Alberti K, Gray C: Blood pressure response to glucose potassium insulin therapy in patiens with acute stroke with mild to moderate hyperglycaemia. J Neurol Neurosurg Psych 70:401–404, 2001
Szabo Z, Arnqvist H, Hakanson E, Jorfeldt L, Svedjeholm R: Effects of high-dose glucose-insulin-potassium on myocardial metabolism after coronary surgery in patients with type II diabetes. Clin Sci (Lond) 101:37–43, 2001
Ramanathan T, Shirota K, Morita S, Nishimura T, Huang Y, Hunyor S: Glucose-insulin-potassium solution improved left ventricular mechanics in diabetes. Ann Thorac Surg 73:582–587, 2002
Svedjeholm R, Huljebrant I, Hakanson E, Vanhanen I: Glutamate and high-dose glucose-insulin-potassium (GIK) in the treatment of severe cardiac failure after cardiac operations. Ann Thorac Surg 59:S23–S30, 1995
Apstein CS, Taegtmeyer H: Glucose-insulin-potassium in acute myocardial infarction: the time has come for a large, prospective trial. Circulation 96:1074–1077, 1997
Weiss JN, Lamp ST: Glycolysis preferentially inhibits ATP-sensitive K+ channels in isolated guinea pig cardiac myocytes. Science 238:67–69, 1987
Mallet RT, Hartman DA, Bunger R: Glucose requirement for postischemic recovery of perfused working heart. Eur J Biochem 188:481–493, 1990
Eberli FR, Weinberg EO, Grice WN, Horowitz GL, Apstein CS: Protective effect of increased glycolytic substrate against systolic and diastolic dysfunction and increased coronary resistance from prolonged global underperfusion and reperfusion in isolated rabbit hearts perfused with erythrocyte suspensions. Circ Res 68:466–481, 1991
Oliver MF, Opie LH: Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet 343:155–158, 1994
Xu KY, Zweier JL, Becker LC: Functional coupling between glycolysis and sarcoplasmic reticulum Ca2+ transport. Circ Res 77:88–97, 1995
Manzella D, Grella R, Marfella R, Giugliano D, Paolisso G: Elevated post-prandial free fatty acids are associated with cardiac sympathetic overactivity in type II diabetic patients. Diabetologia 45:1737–1738, 2002
Oliver MF: Metabolic causes and prevention of ventricular fibrillation during acute coronary syndromes. Am J Med 112:305–311, 2002
Zhu P, Lu L, Xu Y, Greyson C, Schwartz GG: Glucose-insulin-potassium preserves systolic and diastolic function in ischemia and reperfusion in pigs. Am J Physiol Heart Circ Physiol 278:H595–H603, 2000
Szabo Z, Hakanson E, Jorfeldt L, Svedjeholm R: Myocardial uptake and release of substrates in type II diabetics undergoing coronary surgery. Scand Cardiovasc J 35:207–211, 2001
Stanley AW, Jr., Moraski RE, Russell RO, Rogers WJ, Mantle JA, Kreisberg RA, McDaniel HG, Rackley CE: Effects of glucose-insulin-potassium on myocardial substrate availability and utilization in stable coronary artery disease: studies on myocardial carbohydrate, lipid and oxygen arterial-coronary sinus differences in patients with coronary artery disease. Am J Cardiol 36:929–937, 1975
Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD: Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release. J Clin Invest 94:1172–1179, 1994
Cardillo C, Nambi S, Kilcoyne C, Choucair W, Katz A, Quon M, Panza J: Insulin stimulates both endothelin and nitric oxide activity in the human forearm. Circulation 100:820–825, 1999
Chaudhuri A, Kanjwal Y, Mohanty P, Rao S, Sung BH, Wilson MF, Dandona P: Insulin-induced vasodilatation of internal carotid artery. Metabolism 48:1470–1473, 1999
Vehkavaara S, Makimattila S, Schlenzka A, Vakkilainen J, Westerbacka J, Yki-Jarvinen H: Insulin therapy improves endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol 20:545–550, 2000
Rask-Madsen C, Ihlemann N, Krarup T, Christiansen E, Kober L, Nervil Kistorp C, Torp-Pedersen C: Insulin therapy improves insulin-stimulated endothelial function in patients with type 2 diabetes and ischemic heart disease. Diabetes 50:2611–2618, 2001
Gaenzer H, Neumayr G, Marschang p, Sturm W, Lechleitner M, Foger B, Kirchmair R, Patsch J: Effect of insulin therapy on endothelium-dependent dilation in type 2 diabetes mellitus. Am J Cardiol 89:431–434, 2002
Evans M, Anderson R, Smith J, Khan N, Graham J, Thomas A, Morris K, Deely D, Frenneaux M, Davies J, Rees A: Effects of insulin lispro and chronic vitamin C therapy on postprandial lipaemia, oxidative stress and endothelial function in patients with type 2 diabetes mellitus. Eur J Clin Invest 33:231–238, 2003
Arcaro G, Cretti A, Balzano S, Lechi A, Muggeo M, Bonora E, Bonadonna R: Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation 105:576–582, 2002
Aljada A, Dandona P: Effect of insulin on human aortic endothelial nitric oxide synthase. Metabolism 49:147–150, 2000
Hansen T, Thiel S, Wouters P, Christiansen J, VandenBerghe B: Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-gind lectin levels. J Clin Endocrinol Metab 88:1082–1088, 2003
Aikawa R, Nawano M, Gu Y, Katagiri H, Asano T, Zhu W, Nagai R, Komuro I: Insulin prevents cardiomyocytes from oxidative stress-induced apoptosis through activationof PI3 kinase/Akt. Circulation 102:2873–2879, 2000
Aljada A, Saadeh R, Assian E, Ghanim H, Dandona P: Insulin inhibits the expression of intercellular adhesion molecule-1 by human aortic endothelial cells through stimulation of nitric oxide. J Clin Endocrinol Metab 85:2572–2575, 2000
Aljada A, Ghanim H, Saadeh R, Dandona P: Insulin inhibits NFkappaB and MCP-1 expression in human aortic endothelial cells. Journal of Clinical Endocrinol Metab 86:450–453, 2001
Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, Ahmed S: Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocr Metab 86:3257–3265, 2001
Aljada A, Ghanim H, Mohanty P, Kapur N, Dandona P: Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. J Clin Endocr Metab 87:1419–1422, 2002
Jonassen A, Sack M, Mjos O, Yellon D: Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 89:1191–1198, 2001
Guazzi M, Brambilla R, Vita SD, Guazzi M: Diabetes worsens pulmonary diffusion in heart failure, and insulin counteracts this effect. Am J Respir Crit Care Med 166:978–982, 2002
Wiener C, Sylvester J: Effects of insulin, glucose analogues, and pyruvate on vascular responses to anoxia in isolated ferret lungs. J Appl Physiol 74:2426–2431, 1993
Hamilton MG, Tranmer BI, Auer RN: Insulin reduction of cerebral infarction due to transient focal ischemia. J Neurosurg 82:262–268, 1995
Melin J, Hellberg L, Larsson E, Zezina L, Fellstrom B: Protective effect of insulin on ischemic renal injury in diabetes mellitus. Kidney Int 61:1383–1392, 2002
Gore D, Wolf S, Herndon D, Wolfe R: Relative influence of glucose and insulin on peripheral amino acid metabolism in severely burned patients. J Parenter Enter Nutr 26:271–277, 2002
Westerbacka J, Yki-Jarvinen H, Turpeinen A, Rissanen A, Vehkavaara S, Syrjala M, Lassila R: Inhibition of platelet-collagen interaction: an in vivo action of insulin abolished by insulin resistance in obesity. Arterioscler Thromb Vasc Biol 22:167–172, 2002
Levetan CS, Magee MF: Hospital management of diabetes. Endocrinol Metab Clin North Am 29:745–770, 2000
Leahy JL, Bonner-Weir S, Weir GC: β-cell dysfunction induced by chronic hyperglycemia: current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care 15:442–455, 1992
Pomposelli J, Baxter J, Babineau T, Pomfret E, Driscoll D, Forse R, Bistrian B: Early postopertive glucose control predicts nosocomial infection rate in diabetic patients. J Parenter Enter Nutr 22:77–81, 1998
Capes S, Hunt D, Malmberg K, Gerstein H: Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 355:773–778, 2000
Bolk J, van der Ploeg T, Cornel JH, Arnold AE, Sepers J, Umans VA: Impaired glucose metabolism predicts mortality after a myocardial infarction. Int J Cardiol 79:207–214, 2001
Malmberg K, Rydén L, Efendic S, Herlitz J, Nicol P, Waldenström A, Wedel H, Welin L: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 26:57–65, 1995
Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, Piegas L, Calvin J, Keltai M, Budaj A: Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 102:1014–1019, 2000
Furnary A, Zerr K, Grunkemeier G, Starr A: Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 67:352–362, 1999
Furnary AP, Gao G, Grunkemeier GL, Wu Y, Zerr KJ, Bookin SO, Floten HS, Starr A: Continuous insulin infusion reduces mortality in patients wth diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 125:1007–1021, 2003
Zerr KJ, Furnary AP, Grunkemeier GL, Bookin S, Kanhere V, Starr A: Glucose control lowers the risk of wound infection in diabetics after open heart operations. Ann Thorac Surg 63:356–361, 1997
Golden S, Peart-Vigilance C, Kao W, Brancati F: Perioperative glycemic control and the risk of infectious complications in a cohort of adults with diabetes. Diabetes Care 22:1408–1414, 1999
Van den Berghe G, Wouters PJ, Bouillon R, Weekers F, Verwaest C, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P: Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med 31:359–366, 2003
Bruno A, Biller J, Adams HP, Jr., Clarke WR, Woolson RF, Williams LS, Hansen MD: Acute blood glucose level and outcome from ischemic stroke: Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Neurology 52:280–284, 1999
Pulsinelli WA, Levy DE, Sigsbee B, Scherer P, Plum F: Increased damage after ischemic stroke in patients with hyperglycemia with or without established diabetes mellitus. Am J Med 74:540–544, 1983
Demchuk AM, Morgenstern LB, Krieger DW, Linda Chi T, Hu W, Wein TH, Hardy RJ, Grotta JC, Buchan AM: Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke 30:34–39, 1999
Kiers L, Davis SM, Larkins R, Hopper J, Tress B, Rossiter SC, Carlin J, Ratnaike S: Stroke topography and outcome in relation to hyperglycaemia and diabetes. J Neurol Neurosurg Psychiatry 55:263–270, 1992
Williams LS, Rotich J, Qi R, Fineberg N, Espay A, Bruno A, Fineberg SE, Tierney WR: Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke. Neurology 59:67–71, 2002
Scott JF, Robinson GM, French JM, O’Connell JE, Alberti KG, Gray CS: Prevalence of admission hyperglycaemia across clinical subtypes of acute stroke. Lancet 353:376–377, 1999
Brady P, Terzic A: The sulfonylurea controversy: more questions from the heart. J Am Coll Cardiol 31:950–956, 1998
Howes L, Sundaresan P, Lykos D: Cardiovascular effects of oral hypoglycemic drugs. Clin Exp Pharmacol Physiol 23:201–206, 1996
Meinert C, Knatterud G, Prout T, Klimt C, University Group Diabetes Program: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes II: mortality results. Diabetes 19:789–830, 1970
UKPDS Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853, 1998
Murry C, Jennings R, Reimer K: Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74:1124–1136, 1986
Deutsch E, Berger M, Kussmaul W, Hirshfeld J, Herrmann H, Laskey W: Adaptation to ischemia during percutaneous transluminal coronary angioplasty: clinic, hemodynamic, and metabolic features. Circulation 82:2044–2051, 1990
Terzic A, Jahangir A, Kurachi Y: Cardiac ATP-sensitive K+ channels: regulation by intracellular nucleotides and K+ channel-opening durgs. Am J Physiol 269:C525–C545, 1995
Engler R, Yellon D: Sulfonylurea K-ATP blockade in type II diabets and preconditioning in cardiovascular disease: time for reconsideration. Circulation 94:2297–2301, 1996
Cleveland J, Meldrum D, Cain B, Banerjee A, Harken A: Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium: two paradoxes revisited. Circulation 96:29–32, 1997
Tomai F, Crea F, Gaspardone A, Versaci F, Paulis RD: Ishemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation 90:700–705, 1994
Horimoto H, Nakai Y, Mieno S, Nomura Y, Nakahara K, Sasaki S: Oral hypoglycemic sulfonylurea glimepiride preserves the myoprotective effects of ischemic preconditioning. J Surg Res 105:181–188, 2002
Gribble F, Tucker S, Seino S, Ashcroft F: Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels. Diabetes 47:1412–1418, 1998
Legtenberg R, Houston R, Oeseburg B, Smits P: Effects of sulfonylurea derivatives on ischemia-induced loss of function in the isolated rat heart. Eur J Pharmacol 419:85–92, 2001
Mocanu M, Maddock H, Baxter G, Lawrence C, Standen N, Yellon D: Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 103:3111–3116, 2001
Nieszner E, Posa I, Kocsis E, Pogatsa G, Preda I, Koltai M: Influence of diabetic state and that of different sulfonylureas on the size of myocardial infarction with and without ischemic preconditioning in rabbits. Exper Clin Endocr Diab 110:212–218, 2002
Klepzig H, Kober G, Matter C, Luus H, Schneider H, Boedeker K, Kiowski W, Amann F, Gruber D, Harris S, Burger W: Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 20:439–446, 1999
Legtenberg R, Houston R, Smits P, Oeseburg B: Hemodynamic changes caused by glibenclamide in isolated, working, erythrocyte perfused rat heart. Advances in Exper Med Biol 471:257–263, 1999
Najeed S, Khan I, Molnar J, Somberg J: Differential effect of glyburide (glibenclamide) and metformin on QT dispersion: a potential adenosine triphosphate sensitive K+ channel effect. Am J Cardiol 90:1103–1106, 2002
Dhein S, Pejman P, Krusemann K: Effects of the I(K.ATP) blockers glibenclamide and HMR 1883 on cardiac electrophysiology during ischemia and reperfusion. Eur J Pharmacology 398:273–284, 2000
Ren J, Dominguez L, Sowers J, Davidoff A: Metformin but not glyburide prevents high glucose-induced abnormalities in relaxation and intracellular Ca++ transients in adult rat ventricular myocytes. Diabetes 48:2059–2065, 1999
Scognamiglio R, Avogaro A, Kreutzenberg Sd, Negut C, Palisi M, Bagolin E, Tiengo A: Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes. Diabetes 51:808–812, 2002
Garratt KN, Brady PA, Hassinger NL, et al.: Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 33:119–124, 1999
O’Keefe J, Blackstone E, Sergeant P, McCallister B: The optimal mode of coronary revascularization for diabetics. Eur Heart J 19:1696–1703, 1998
Aronow W, Ahn C: Incidence of new coronary events in older persons with diabetes mellitus and prior myocardial infarction treated with sulfonylureas, insulin metformin and diet alone. Am J Cardiol 88:556–557, 2001
Klamann A, Sarfert P, Launhardt V, Schulte G, Schmiegel W, Nauck M: Myocardial infarction in diabetic vs nondiabetic subjects: sruvival and infarct size following therapy with sulfonylureas (glibenclamide). Eur Heart J 21:220–229, 2000
Brady P, Al-Suwaidi J, Kopecky S, Terzic A: Sulfonylureas and mortality in diabetic patients after myocardial infarction. Circulation 97:709–710, 1998
Davis T, Parsons R, Broadhurst R, Hobbs M, Jamrozik K: Arrhythmias and mortality after myocardial infarction in diabetic patients: relationship to diabetes treatment. Diabetes Care 21:637–640, 1998
Halkin A, Roth A, Jonas M, Behar S: Sulfonylureas are not associated with increased mortality in diabetics treated with thrombolysis for acute myocardial infarction. J Thromb Thrombolysis 12:177–184, 2001
Jollis J, Simpson R, Cascio W, Chowdhury M, Crouse J, Smith S: Relation between sulfonylurea therapy, complicaions, and outcome for elderly patients with acute myocardial infarction. Am Heart J 128:S376–S380, 1999
Weih M, Amberger N, Wegener S, Dirnagl U, Reuter T, Einhaupl K: Sulfonylurea drugs do not influenced initial stroke severity and in-hospital outcome in stroke patients with diabetes. Stroke 32:2029–2032, 2001
Malmberg K, Norhammar A, Wedel H, Ryden L: Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose infusion in Acute Myocardial Infarction (DIGAMI) Study. Circulation 99:2626–2632, 1999
Miller C, Phillips L, Ziemer D, Gallina D, Cook C, El-Kebbi I: Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 161:1653–1659, 2001
Harrower A: Comparative tolerability of sulphonylureas in diabetes mellitus. Drug Safety 22:313–320, 2000
UKPDS Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865, 1998
Misbin R, Green L, Stadel B, Gueriguian J, Gubbi A, Alexander G: Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 338:265–266, 1998
Emslie-Smith A, Boyle D, Evans J, Sullivan F, Morris A: Contraindications to metformin therapy in patients with type 2 diabetes: a population-based study of adherence to prescribing guidelines. Diabet Med 18:483–488, 2001
Horlen C, Malone R, Bryant B, Dennis B, Carey T, Pignone M, Rothman R: Frequency of inappropriate metformin prescriptions. JAMA 287:2504–2505, 2002
Sulkin T, Bosman D, Krentz A: Contraindications to metformin therapy in patients with NIDDM. Diabetes Care 20:925–928, 1997
Calabrese A, Coley K, DaPos S, Swanson D, Rao R: Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med 162:434–437, 2002
Masoudi FA, Wang Y, Inzucchi SE, Setaro JF, Havranek EP, Foody JM, Krumholz HM: Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA 290:81–85, 2003
Salpeter S, Greyber E, Pasternak G, Salpeter E: Metformin does not increase fatal or nonfatal lactic acidosis or blood lactate levels in type 2 diabetes mellitus (Review Article). Cochrane Database Syst Rev 2:CD002967, 2002
Malinowski J, Bolesta S: Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review. Clin Ther 22:1151–1168, 2000
Idris I, Gray S, Donnelly R: Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability. Diabetologia 46:488–490, 2003
Choi S, Choi D, Ko Y, Chang YS, Cho Y, Lim S, Nam M, Lee H, Cha B: Preventive effects of rosiglitazone on restenoss after coronary stenting in patients with type 2 diabetes (Abstract). Diabetes 52 (Suppl. 1):A19, 2003
Lalli C, Ciofetta M, Del Sindaco P, Torlone E, Pampanelli S, Compagnucci P, Cartechini MG, Bartocci L, Brunetti P, Bolli GB: Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 22:468–477, 1999
Clement S, Still JG, Kosutic G, McAllister RG: Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: the glucose stabilization effects of HIM2. Diabetes Technol Ther 4:459–466, 2002
Queale WS, Seidler AJ, Brancati FL: Glycemic control and sliding scale insulin use in medical inpatients with diabetes mellitus. Arch Intern Med 157:545–552, 1997
Gearhart J, Duncan JL, Replogle WH, Forbes RC, Walley EJ: Efficacy of sliding-scale insulin therapy: a comparison with prospective regimens. Fam Pract Res J 14:313–322, 1994
Walts LF, Miller J, Davidson MB, Brown J: Perioperative management of diabetes mellitus. Anesthesiology 55:104–109, 1981
Kidson W, Casey J, Kraegen E: Treatment of severe diabetes mellitus by insulin infusion. Br Med J 2:691–694, 1974
Page MM, Alberti KG, Greenwood R, Gumaa KAA, Hockaday TD, Lowy C, Nabarro JD, Pyke DA, Sonksen PH, Watkins PJ, West TE: Treatment of diabetic coma with continuous low dose infusion of insulin. Br Med J 2:687–690, 1974
Semple PF, White C, Manderson WG: Continuous intravenous infusion of small doses of insulin in treatment of diabetic ketoacidosis. Br Med J 2:694–698, 1974
Soler NG, FitzGerald MG, Wright AD, Malins JM: Comparative study of different insulin regimens in management of diabetic ketoacidosis. Lancet 2:1221–1224, 1975
Kitabchi AE, Ayyagari V, Guerra SMO: The efficacy of low-dose versus conventional therapy of insulin for treatment of diabetic ketoacidosis. Ann Intern Med 84:633–638, 1976
Alberti KGMM: Comparison of different insulin regimens in diabetic ketoacidosis. Lancet 1:83–84, 1976
Alberti KGMM: Low-dose insulin in the treatment of diabetic detoacidosis. Arch Intern Med 137:1367–1376, 1977
Fisher JN, Shahshahani MN, Kitabchi AE: Diabetic ketoacidosis: low-dose insulin therapy by various routes. N Engl J Med 297:238–241, 1977
Sacks HS, Shahshahani M, Kitabchi AE, Fisher JN, Young RT: Similar responsiveness of diabetic ketoacidosis to low-dose insulin by intramuscular injection and albumin-free infusion. Ann Intern Med 90:36–42, 1979
Berger W, Keller U: Treatment of diabetic ketoacidosis and nonketotic hyperosmolar diabetic coma. Baillieres Clin Endocrinol Metab 6:1–22, 1992
Siperstein MD: Diabetic ketoacidosis and hyperosmolar coma. Endocrinol Metab Clin North Am 21:415–432, 1992
Umpierrez GE, Kelly JP, Navarrete JE: Hyperglycemic crises in urban blacks. Arch Intern Med 157:669–675, 1997
Wagner A, Risse A, Brill HL, Wienhausen-Wilke V, Rottman M, Sondern K, Angelkort B: Therapy of severe diabetic ketoacidosis: zero-mortality under very-low-dose insulin application. Diabetes Care 22:674–677, 1999
Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, Kreisberg RA, Malone JI, Wall BM: Management of hyperglycemic crises in patients with diabetes. Diabetes Care 24:131–153, 2001
Gill GV, Sherif IH, Alberti KG: Management of diabetes during open heart surgery. Br J Surg 68:171–172, 1981
Alberti KG, Gill GV, Elliot MJ: Insulin delivery during surgery in the diabetic patient. Diabetes Care 5 (Suppl. 1):65–67, 1982
Thomas DJ, Platt HS, Alberti KG: Insulin-dependent diabetes during the peri-operative period: an assessment of continuous glucose-insulin-potassium infusion, and traditional treatment. Anaesthesia 39:629–637, 1984
Husband DJ, Thai AC, Alberti KG: Management of diabetes during surgery with glucose-insulin-potassium infusion. Diabet Med 3:69–74, 1986
Watts NB, Gebhart SSP, Clark RV, Phillips LS: Postoperative mangement of diabetes mellitus: steady-state glucose control with bedside algorithm for insulin adjustment. Diabetes Care 10:722–728, 1987
Pezzarossa A, Taddei F, Cimicchi MC, Rossini E, Contini S, Bonora E, Gnudi A, Uggeri E: Perioperative management of diabetic subjects: subcutaneous versus intravenous insulin administration during glucose-potassium infusion. Diabetes Care 11:52–58, 1988
Hirsch IB, McGill JB: Role of insulin in management of surgical patients with diabetes mellitus. Diabetes Care 13:980–991, 1990
Gavin LA: Perioperative management of the diabetic patient. Endocrin Metab Clin North Am 21:457–475, 1992
Schiff RL, Emanuele MA: The surgical patient with diabetes mellitus: guidelines for management. J Gen Intern Med 10:154–161, 1995
Gill GV, Alberti KGMM: The care of the diabetic patient during surgery. In International Textbook of Diabetes Mellitus. Alberti KGMM, Zimmet P, Keen H, DeFronzo RA, Eds. Chichester, Wiley, 1992, p. 1173–1183
Avilés-Santa L, Raskin P: Surgery and anesthesia. In Therapy for Diabetes Mellitus and Related Disorders. 3rd ed. Lebovitz HE, Ed. Alexandria, VA, ADA, 1998, p. 224–233
Surgery. In Medical Management of Type 1 Diabetes. Kelley DB, Ed. Alexandria, VA, ADA, 1998, p. 159–163
Ahmann A: Comprehensive management of the hospitalized patient with diabetes. Endocrinologist 8:250–259, 1998
Hill A: Continuous intravenous insulin infusion in patients with diabetes after cardiac surgery. Clin Nurse Spec 16:93–95, 2002
Mittra B: Potassium, glucose, and insulin in treatment of myocardial infarction. Lancet 2:607–609, 1965
Hendra TJ, Yudkin JS: An algorithm for tight glycaemic control in diabetic infarct survivors. Diabetes Res Clin Pract 16:213–220, 1992
Malmberg KA, Efendic S, Ryden LE: Feasibility of insulin-glucose infusion in diabetic patients with acute myocardial infarction. Diabetes Care 17:1007–1014, 1994
Fath-Ordoubadi F, Beatt KJ: Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomzied placebo-controlled trials. Circulation 96:1152–1156, 1997
Kjellman UW, Bjork K, Dahlin A, Ekroth R, Kirno K, Svensson G, Wernerman J: Insulin (GIK) improves myocardial metabolism in patients during blod cardioplegia. Scand Cardiovasc J 34:321–330, 2000
Braithwaite S: Detection and management of diabetes mellitus during glucocorticoid therapy of nonendocrine disease. In Endocrine Replacement Therapy in Clinical Practice. Meikle AW, Ed. Totowa, NJ, Humana Press, 2003, p. 251–282
Hirsch IB, Paauw DS, Brunzell J: Inpatient management of adults with diabetes. Diabetes Care 18:870–878, 1995
McWilliam DB: The practical management of glucose-insulin infusions in the intensive care patient. Intensive Care Med 6:133–135, 1980
Woolfson AM: Control of blood glucose during nutritional support in ill patients. Intensive Care Med 7:11–14, 1980
Brown G, Dodek P: Intravenous insulin nomogram improves blood glucose control in the critically ill. Crit Care Med 29:1714–1719, 2001
White NH, Skor D, Santiago JV: Practical close-loop insulin delivery: a system for the maintenance of overnight euglycemia and the calculation of basal insulin requirements in insulin-dependent diabetics. Ann Intern Med 97:210–213, 1982
Mao CS, Riegelhuth ME, Van Gundy D, Cortez C, Melendez S, Ipp E: An overnight insulin infusion algorithm provides morning normoglycemia and can be used to predict insulin requirements in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:2466–2470, 1997
Hawkins JB, Jr., Morales CM, Shipp JC: Insulin requirement in 242 patients with type II diabetes mellitus. Endocr Pract 1:385–389, 1995
Hemmerling TM, Schmid MC, Schmidt J, Kern S, Jacobi KE: Comparison of a continuous glucose-insulin-potassium infusion versus intermittent bolus application of insulin on perioperative glucose control and hormone status in insulin-treated type 2 diabetics. J Clin Anesth 13:293–300, 2001
Hirsch IB, Paauw DS: Diabetes management in special situations. Endocr Metab Clin North Am 26:631–645, 1997
Quevedo SF, Sullivan E, Kington R, Rogers W: Improving diabetes care in the hospital using guideline-directed orders. Diabetes Spectrum 14:226–233, 2001
Peterson L, Caldwell J, Hoffman J: Insulin adsorbance to polyvinylchloride surfaces with implications for constant-infusion therapy. Diabetes 25:72–74, 1976
Turner RC, Grayburn JA, Newman GB: Measurement of the insulin delivery rate in man. J Clin Endocrinol Metab 33:279–286, 1971
Clumeck N, Detroyer A, Naeije R: Small intravenous insulin boluses in the treatment of diabetic coma. Lancet 2:416, 1975
Dunnett M, Steemson J, Sear JW, Turner RC, Holman RR: Rapid restoration of normoglycaemia using intravenous insulin boluses. Diabetes Res 15:151–155, 1990
Beyer J, Krause U, Dobronz A, Fuchs B. Delver JR, Wagner R: Assessment of insulin needs in insulin-dependent diabetics and healthy volunteers under fasting conditions. Horm Metab Res 24 (Suppl.):71–77, 1990
Mokan M, Gerich JE: A simple insulin infusion algorithm for establishing and maintaining overnight near-normoglycemia in type I and type II diabetes. J Clin Endocrinol Metab 74:943–945, 1992
Markovitz L, Wiechmann R, Harris N, Hayden V, Cooper J, Johnson G, Harelstad R, Calkins L, Braithwaite SS: Description and evaluation of a glycemic management protocol for diabetic patients undergoing heart surgery. Endocr Pract 8:10–18, 2002
Latham R, Lancaster AD, Covington JF, Pirolo JS, Thomas CS: The association of diabetes and glucose control with surgical-site infections among cardiothoracic surgery patients. Infect Control Hosp Epidemiol 22:607–612, 2001
Carson JL, Scholz PM, Chen AY, Peterson ED, Gold J, Schneider SH: Diabetes mellitus increases short-term mortality and morbidity in patients undergoing coronary artery bypass graft surgery. J Am Coll Cardiol 40:418–423, 2002
Metchick LN, Petit WA, Jr., Inzucchi SE: Inpatient management of diabetes mellitus. Am J Med 113:317–323, 2002
Mitka M: Rethinking treatment for patients with diabetes and cardiovascular disease. JAMA 287:2488–2491, 2002
Szabo Z, Hakanson E, Svedjeholm R: Early postoperative outcome and medium-term survival in 540 diabetic and 2239 nondiabetic patients undergoing coronary artery bypass grafting. Ann Thorac Surg 74:712–719, 2002
Intensive Diabetes Management. 2nd ed. Alexandria, VA, ADA, 1998
Etzwiler DD: Diabetes transition: a blueprint for the future. Diabetes Care 17:1–4, 1994
Institute of Medicine: Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, D.C., Academia Press, 2001
Peterson CM, Forhan SE, Jones RL: Self-management: an approach to patients with insulin dependent diabetes mellitus. Diabetes Care 3:82–87, 1980
Greenfield S, Kaplan SH, Ware JE Jr, Yano EM, Frank HJ: Patients’ participation in medical care: effects on blood sugar control and quality of life in diabetes. J Gen Intern Med 3:448–457, 1988
The Diabetes Control and Complications Trial Research Group (DCCT): The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986, 1993
Bode BW, Steed RD, Davidson PC: Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes Care 19:324–327, 1996
Rudolph JW, Hirsch IB: Assessment of therapy with continuous subcutaneous insulin infusion in an academic diabetes clinic. Endocrine Practice 8:401–405, 2002
Anderson JH, Brunelle RL, Keohane P, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R: Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med 157:1249–1255, 1997
Anderson JH, Brunelle RL, Koivisto VA, Pfützner A, Trautmann ME, Vignati L, DiMarchi R: Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes 46:265–270, 1997
Lindholm A, McEwen J, Riis AP: Improved postprandial glycemic control with insulin aspart. Diabetes Care 22:801–805, 1999
Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L: Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 23:583–588, 2000
Pieber TR, Eugene-Jolchine IE, Derobert E: Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. Diabetes Care 23:157–162, 2000
Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA: Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 23:639–643, 2000
Hermansen K, Madsbad S, Perrild H, Kristensen A, Azelsen M: Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 24:296–301, 2001
Rosenstock J, Schwartz S, Clark C, Park G, Donley D, Edwards M: Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24:631–636, 2001
Rosenstock J, Park G, Zimmerman J: Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care 23:1137–1142, 2000
Pfutzner A, Kustner E, Forst T, Schultze-Schleppinghoff B, Trautmann ME, Haslbeck M, Schatz H, Beyer J: Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemia episodes. Exp Clin Endocrinol Diabetes 104:25–30, 1996
Zinman B, Tildesley H, Chiasson J-L, Tsui E, Strack T: Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 46:440–443, 1997
Renner R, Pfutzner A, Trautmann M, Harzer O, Sauter K, Landgraf R: Use of insulin lispro in continuous subcutaneous insulin infusion treatment: results of a multicenter trial. Diabetes Care 784–788, 1999
Warshaw HS, Bolderman KM: Advanced carbohydrate counting. In Practical Carbohydrate Counting: A How-to-Teach Guide for Health Professionals. Alexandria, VA, ADA, 2001, p. 26–28
DAFNE Study Group: Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. BMJ 325:746, 2002
Malouf R, Brust JC: Hypoglycemia: causes, neurological manifestations, and outcome. Ann Neurol 17:421–430, 1985
Ben-Ami H, Nagachandran P, Mendelson A, Edoute Y: Drug-induced hypoglycemic coma in 102 diabetic patients. Archives of Internal Medicine 159:281–284, 1999
Weston PJ, Gill GV: Is undetected autonomic dysfunction responsible for sudden death in Type 1 diabetes mellitus? The “dead in bed” syndrome revisited. Diabet Med 16:626–631, 1999
Cryer PE: Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 45:937–948, 2002
Shilo S, Berezovsky S, Friedlander Y, Sonnenblick M: Hypoglycemia in hospitalized nondiabetic older patients. J Am Geriat Socy 46:978–982, 1998
Fischer KF, Lees JA, Newman JH: Hypoglycemia in hospitalized patients. N Engl J Med 315:1245–1250, 1986
Gaster B, Hirsch IB: Sliding scale insulin use and rates of hyperglycemia. Arch Intern Med 158:95, 1998
Young M: Hypoglycaemia; a nursing care study. Nurs Times 66:915–916, 1970
Peragallo-Dittko V: Diabetes 2000: acute complications. RN 58:36–41, 1995
Watters JM, Kirkpatrick SM, Hopbach D, Norris SB: Aging exaggerates the blood glucose response to total parenteral nutrition. Can J Surg 39:481–485, 1996
Bjerke HS, Shabot MM: Glucose intolerance in critically ill surgical patients: relationship to total parenteral nutrition and severity of illness. Am Surg 58:728–731, 1992
Rosmarin DK, Wardlaw GM, Mirtallo J: Hyperglycemia associated with high, continuous infusion rates of total parenteral nutrition dextrose. Nutr Clin Pract 11:151–156, 1996
Park RH, Hansell DT, Davidson LE, Henderson G, Legge V, Gray GR: Management of diabetic patients requiring nutritional support. Nutrition 8:316–320, 1992
Woolfson AM: An improved method for blood glucose control during nutritional support. J Parenter Enteral Nutr 5:436–440, 1981
Sajbel TA, Dutro MP, Radway PR: Use of separate insulin infusions with total parenteral nutrition. J Parenter Enteral Nutr 11:97–99, 1987
Hollingdal M, Juhl CB, Dall R, Sturis J, Veldhuis JD, Schmitz O, Porksen N: Glucocorticoid induced insulin resistance impairs basal but not glucose entrained high-frequency insulin pulsatility in humans. Diabetologia 45:49–55, 2002
Boyle PJ: Cushings disease, glucocorticoid excess, glucocorticoid deficiency, and diabetes. Diabetes Reviews 1:301, 1993
Lambillotte C, Gilon P, Henquin JC: Direct glucocorticoid inhibition of insulin secretion: an in vitro study of dexamethasone effects in mouse islets. J Clin Invest 99:414–423, 1997
Dimitriadis G, Leighton B, Parry-Billings M, Sasson S, Young M, Krause U, Bevan S, Piva T, Wegener G, Newsholme EA: Effects of glucocorticoid excess on the sensitivity of glucose transport and metabolism to insulin in rat skeletal muscle. Biochem J 321:707–712, 1997
Shamoon H, Soman V, Sherwin RS: The influence of acute physiological increments of cortisol on fuel metabolism and insulin binding to monocytes in normal humans. J Clin Endocrinol Metab 50:495–501, 1980
Wachtel TJ, Tetu-Mouradjian LM, Goldman DL, Ellis SE, O’Sullivan PS: Hyperosmolarity and acidosis in diabetes mellitus: a three-year experience in Rhode Island. J Gen Intern Med 6:495–502, 1991
Willi SM, Kennedy A, Brant BP, Wallace P, Rogers NL, Garvey WT: Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes. Diabetes Res Clin Pract 58:87–96, 2002
Ravina A, Slezak L, Mirsky N, Bryden NA, Anderson RA: Reversal of corticosteroid-induced diabetes mellitus with supplemental chromium. Diabet Med 16:164–167, 1999
Coulston AM: Enteral nutrition in the patient with diabetes mellitus. Curr Opin Clin Nutr Metab Care 3:11–15, 2000
Haddad RY, Thomas DR: Enteral nutrition and enteral tube feeding: review of the evidence. Clin Geriatr Med 18:867–881, 2002
Sanz-Paris A, Calvo L, Guallard A, Salazar I, Albero R: High-fat versus high-carbohydrate enteral formulae: effect on blood glucose, C-peptide, and ketones in patients with type 2 diabetes treated with insulin or sulfonylurea. Nutrition 14:840–845, 1998
Peters AL, Davidson MB, Isaac RM: Lack of glucose elevation after simulated tube feeding with a low-carbohydrate, high-fat enteral formula in patients with type I diabetes. Am J Med 87:178–182, 1989
Craig LD, Nicholson S, SilVerstone FA, Kennedy RD: Use of a reduced-carbohydrate, modified-fat enteral formula for improving metabolic control and clinical outcomes in long-term care residents with type 2 diabetes: results of a pilot trial. Nutrition 14:529–534, 1998
Levetan CS, Salas JR, Wilets IF, Zumoff B: Impact of endocrine and diabetes team consultation on hospital length of stay for patients with diabetes. Am J Med 99:22–28, 1995
Koproski J, Pretto Z, Poretsky L: Effects of an intervention by a diabetes team in hospitalized patients with diabetes. Diabetes Care 290:1553–1555, 1997
Levetan CS, Passaro MD, Jablonski KA, Ratner RE: Effect of physician specialty on outcomes in diabetic ketoacidosis. Diabetes Care 22:1790–1795, 1999
Grol R, Dalhuijsen J, Thomas S, Veld C, Rutten G, Mokkink H: Attributes of clinical guidelines that influence use of guidelines in general practice: observational study. Brit Med J 317:858–861, 1998
Leape LL, Brennan TA, Laird N, Lawthers AG, Localio AR, Barnes BA, Hebert L, Newhouse JP, Weiler PC, Hiatt H: The nature of adverse events in hospitalized patients: results of the Harvard Medical Practice Study II. N Engl J Med 324:377–384, 1991
Lesar TS, Lomaestro BM, Pohl H: Medication-prescribing errors in a teaching hospital: a 9 -year experience. Arch Intern Med 157:1569–1576, 1997
Richardson WC, Berwick DM, Bisgard JC: The institute of medicine report on medical errors. N Engl J Med 343:663–664, 2000
Alberti KGMM: Medical errors: a common problem—it is time to get serious about them. Brit Med J 322:501–502, 2001
Cohen MR, Proulx SM, Crawford SY: Survey of hospital systems and common serious medication errors. J Health Risk Manag 18:16–27, 1998
Institute of Medicine, Committee on Quality of Health Care in America: To Err Is Human: Building a Safer Health System. Kohn LT, Corrigan JM, Donaldson MS, Eds. Washington, D.C., National Academy Press, 1999
Cohen MR: Medication Errors. Washington, D.C., Institute for Safe Medication Practices, American Pharmaceutical Association, 1999
Piotrowski MM, Hinshaw DB: The safety checklist program: creating a culture of safety in intensive care units. Jt Comm J Qual Improv 28:306–315, 2002
Adlersberg MA, Fernando S, Spollett GR, Inzucchi SE: Glargine and lispro: two cases of mistake identity. Diabetes Care 25:404–405, 2002
Crowe DJ: The American Diabetes Association should be a leader in reducing medication errors (Letter). Diabetes Care 24:1841, 2001
Phelps MR, White SJ: The pharmacist’s role in a team approach for diabetic patient education. Hospital Pharmacy 12:78–80, 1977
Hawkins DW, Fiedler FP, Douglas HL, Eschbach RC: Evaluation of a clinical pharmacist in caring for hypertensive and diabetic patients. Am J Hosp Pharm 36:1321–1325, 1979
Huff PS, Ives TJ, Almond SN, Griffin NW: Pharmacist-managed diabetes education service. Am J Hosp Pharm 40:991–994, 1983
Ponte CD: Monitoring the patient with diabetes mellitus: how to avoid medication errors. Hospital Pharm 24:280–283,289, 1989
Brient K: Barcoding facilitates patient-focused care. Healthc Inform 12:38,40,42, 1995
Leape LL, Cullen DJ, Clapp MD, Burdick E, Demonaco HJ, Erickson JI, Bates DW: Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 282:267–270, 1999
Hanish LR: Standardizing regimens for sliding-scale insulin. Am J Health System Pharm 54:1046–1047, 1997
Achtmeyer CE, Payne TH, Anawalt BD: Computer order entry system decreased use of sliding scale insulin regimens. Meth Inform Med 41:277–281, 2002
Spenney JG, Eure CA, Kreisberg RA: Hyperglycemic, hyperosmolar, nonketoacidotic diabetes: a complication of steroid and immunosuppressive therapy. Diabetes 18:107–110, 1969
Ivanova II, Vasiutkova LA, Ivanov VA: Hyperglycemic coma after corticosteroid therapy. Sovetskaia Meditsina 10:112–113, 1984
Bouhanick B, Biquard F, Hadjadj S, Roques MA: Does treatment with antenatal glucocorticoids for the risk of premature delivery contribute to keto-acidosis in pregnant women with diabetes who receive continuous subcutaneous insulin infusion (CSII)? Arch Intern Med 160:242–243, 2000
Brocard H, Akoun G, Grand A: Diabète stéroïde compliqué d’un coma de type hyperosmolaire. Bulletins et Mémoires de la Société Médicale des Hôpitaux de Paris 116:353–363, 1965
Pyörälä K, Suhonen O, Pentikäinen P: Steroid therapy and hyperosmolar non-ketotic coma. Lancet 1:596–597, 1968
Szewczyk Z, Ratajczyk T, Rabczynski J: Hyperosmotic coma in steroid-induced diabetes complicating subacute glomerulonephritis in a 16-year-old boy. Polski Tygodnik Lekarski 26:1988–1990, 1971
Woods JE, Zincke H, Palumbo PJ, Johnson WJ, Anderson CF, Frohnert PP, Service FJ: Hyperosmolar nonketotic syndrome and steroid diabetes. JAMA 231:1261–1263, 1975
Fujikawa LS, Meisler DM, Nozik RA: Hyperosmolar hyperglycemic nonketotic coma. Ophthalmology 90:1239–1242, 1983
Winterstein AG, Hatton RC, Gonzalez-Rothi R, Johns TE, Segal R: Identifying clinically significant preventable adverse drug events through a hospital’s database of adverse drug reaction reports. Am J Health System Pharm 59:1742–1749, 2002
Stagnaro-Green A, Barton M, Linekin P, Corkery E, deBeer K, Roman S: Mortalilty in hospitalized patients with hypoglycemia and severe hyperglycemia. Mount Sinai J Med 62:422–426, 1995
Roman SH, Linekin PL, Stagnaro-Green A: An inpatient diabetes QI program. Jt Comm J Qual Improv 21:693–699, 1995
Roman SH, Chassin MR: Windows of opportunity to improve diabetes care when patients with diabetes are hospitalized for other conditions. Diabetes Care 24:1371–1376, 2001
Gilman JA: A quality improvement project for better glycemic control in hospitalized patients with diabetes. Diabetes Educ 27:541–546, 2001
National health promotion and disease prevention objectives, full report with commentary. In Healthy People 2000. Boston, MA, Jones and Bartlet, 1992, p. 462
Muhlhauser I, Bruckner I, Berger M, Cheta D, Jorgens V, Ionescu-Tirgoviste C, Scholz V, Mincu I: Evaluation of an intensified insulin treatment and teaching programme as routine management of type 1 (insulin-dependent) diabetes: the Bucharest-Dusseldorf Study. Diabetologia 30:681–690, 1987
Feddersen E, Lockwood DH: An inpatient diabetes educator’s impact on length of hospital stay. Diabetes Educ 20:125–128, 1994
Wood ER: Evaluation of a hospital-based education program for patients with diabetes. J Am Diet Assoc 89:354–358, 1989
Shorr RI, Ray WA, Daugherty JR, Griffin MR: Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 157:1681–1686, 1997
Shorr RI, Ray WA, Daugherty JR, Griffin MR: Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriat Soc 44:751–755, 1996
American Diabetes Association: Translation of the diabetes nutrition recommendations for health care institutions. Diabetes Care 20:106–108, 1997
Schafer RG, Bohannon B, Franz M, Freeman J, Holmes A, McLaughlin S, Haas LB, Kruger DF, Lorenz RA, McMahon MM: Translation of the diabetes nutrition recommendations for health care institutions. Diabetes Care 20:96–105, 1997
McMahon MM, Rizza RA: Nutrition support in hospitalized patients with diabetes mellitus. Mayo Clin Proc 71:587–594, 1996
American Diabetes Association: Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications (Position Statement). Diabetes Care 26 (Suppl. 1):S51–S61, 2003
Paddock BW: Carbohydrate counting in institutions. Diabetes Spectrum 13:149–152, 2000
American Diabetes Association: Translation of the diabetes nutrition recommendations for health care institutions (Position Statement). Diabetes Care 26 (Suppl. 1):S70–S72, 2003
Lewandrowski K, Cheek R, Nathan DM, Godine JE, Hurxthal K, Eschenbach K, Laposata M: Implementation of capillary blood glucose monitoring in a teaching hospital and determination of program requirements to maintain quality testing. Am J Med 93:419–426, 1992
Rumley AG: Improving the quality of near-patient blood glucose measurement. Ann Clin Biochem 34 (Pt. 3):281–286, 1997
Tang Z, Lee JH, Louie RF, Kost GJ: Effects of different hematocrit levels on glucose measurements with handheld meters for point-of-care testing. Arch Pathol Lab Med 124:1135–1140, 2000
Atkin SH, Dasmahapatra A, Jaker MA, Chorost MI, Reddy S: Fingerstick glucose determination in shock. Ann Intern Med 114:1020–1024, 1991
Tang Z, Du X, Louie RF, Kost GJ: Effects of drugs on glucose measurements with handheld glucose meters and a portable glucose analyzer. Am J Clin Pathol 113:75–86, 2000
Jain R, Myers TF, Kahn SE, Zeller WP: How accurate is glucose analysis in the presence of multiple interfering substances in the neonate? (Glucose analysis and interfering substances). J Clin Lab Anal 10:13–16, 1996
Bina DM, Anderson RL, Johnson ML, Bergenstal RM, Kendall DM: Clinical impact of prandial state, exercise, and site preparation on the equivalence of alternative-site blood glucose testing. Diabetes Care 26:981–985, 2003
Jones BA, Bachner P, Howanitz PJ: Bedside glucose monitoring: a College of American Pathologists Q-Probes study of the program characteristics and performance in 605 institutions. Arch Pathol Lab Med 117:1080–1087, 1993
Point of Care Blood Glucose Testing n Acute and Chronic Care Facilities; Approved Guideline. 2nd ed. Wayne, PA, NCCLS, 2002
American Diabetes Association: Economic costs of diabetes in the U.S. in 2002. Diabetes Care 26:917–932, 2003
Jiang HJ, Stryer D, Friedman B, Andrews R: Multiple hospitalizations for patients with diabetes. Diabetes Care 26:1421–1426, 2003
Selby JV, Ray GT, Zhang D, Colby CJ: Excess costs of medical care for patients with diabetes in a managed care population. Diabetes Care 20:1396–1402, 1997
Shojana K, Duncan B, Mcdonald K: Making Health Care Safer: A Critical Analysis of Patient Safety Practices. Evidence Report/Technology Assessment No. 43. Rockville, MD, AHRQ publication no. 01-E058, 2001